Gyre Therapeutics Inc.

NASDAQ: GYRE · Real-Time Price · USD
8.11
-0.11 (-1.34%)
At close: Aug 15, 2025, 3:59 PM
8.14
0.37%
After-hours: Aug 15, 2025, 04:04 PM EDT

Gyre Therapeutics Income Statement

Financials in USD. Fiscal year is undefined.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
26.77M 22.06M 27.87M 25.49M 25.23M 27.17M 27.15M 32.04M 26.14M 24.44M -794K 29.17M 23.33M 794K 2.44M 2.3M 1.13M 1.47M
Cost of Revenue
1.15M 894K 1.18M 958K 770K 979K 1.25M 1.18M 318K 588K 798K 803K 67K 798K 2.45M 2.31M 1.14M 1.48M
Gross Profit
25.62M 21.16M 26.7M 24.53M 24.45M 26.19M 25.9M 30.86M 25.82M 23.85M -1.59M 28.37M 23.27M -4K -14K -8K -7K -13K
Operating Income
2.17M 2.27M 597K 4.23M 3.26M 8.07M -91.63M 12.76M -2.54M 178K -40.27M -5.17M 51.53M -14.7M -20.31M -25.23M -19.91M -22.44M
Interest Income
n/a 200K 346K 523K 350K 328K 528.63K 283K n/a 96K 167K 283K 102K n/a 4K 7K 11K 17K
Pretax Income
2.24M 4.63M 772K 3.93M 6.04M 12.48M -100.28M 11.19M -2.47M 274K -40.11M -4.88M 51.63M -14.54M -20.33M -25.24M -19.93M -22.44M
Net Income
442K 2.7M -99K 5M 3.53M 7.53M -52.19M 3.98M 5.6M 5.37M -3.48M -3.34M 4.77M 5.04M -20.33M -25.24M -19.93M -22.44M
Selling & General & Admin
20.02M 15.8M 22.32M 17.52M 17.84M 15.94M 26.52M 15.09M 19.71M 14.51M 4.17M 4.36M 3.84M 14.71M 4.16M 4.87M 4.52M 5.41M
Research & Development
3.42M 3.1M 3.71M 2.77M 3.35M 2.18M 87.67M 3.01M 318K 588K 660K 803K 1.87M 9.7M 16.14M 20.35M 15.39M 17.01M
Other Expenses
1K n/a 66K n/a n/a n/a 3.34M n/a 629K -49.7K n/a n/a 17K -17K -20K -16K -25K -17K
Operating Expenses
23.45M 18.89M 26.1M 20.3M 21.19M 18.12M 117.53M 18.09M 2.54M 4.56M 4.83M 5.17M 5.71M 14.7M 20.3M 25.22M 19.91M 22.43M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 716K 1K 102K 13.68K n/a n/a n/a n/a
Selling & Marketing Expenses
15.19M 10.84M 16.86M 13.7M 14.41M 12.54M 16.46M 13.93M 18M 12.77M n/a n/a n/a 12.71M n/a n/a n/a n/a
Cost & Expenses
24.6M 19.79M 27.27M 21.25M 21.96M 19.1M 118.78M 19.28M 2.54M 4.56M 4.83M 5.17M 5.71M 15.49M 22.75M 27.53M 21.05M 23.91M
Income Tax Expense
662K -901K 203K -1.07M 1.5M 2.55M 699K 3.68M 2K 14K 348K -282K -57.35M -182K -4K -7K -11K -17K
Shares Outstanding (Basic)
89.12M 86.42M 85.09M 85.64M 85.5M 83.27M 76.6M 76.6M 69.95M 69.95M 63.3M 61.05M 62.94M 62.91M 31.42M 31.38M 31.14M 28.39M
Shares Outstanding (Diluted)
102.7M 101.97M 102.29M 102.64M 104.33M 102.59M 76.6M 76.6M 70.09M 70.09M 63.59M 61.05M 62.94M 62.91M 31.42M 31.38M 31.35M 28.39M
EPS (Basic)
n/a 0.03 -0.19 0.06 0.04 0.09 -0.68 0.05 0.08 0.08 -0.06 -0.05 0.08 0.08 -0.65 -0.8 -0.64 -0.79
EPS (Diluted)
n/a 0.00 -0.16 0.05 0.03 0.07 -0.68 0.05 0.08 0.08 -0.05 -0.05 0.08 0.08 -0.65 -0.8 -0.64 -0.79
EBITDA
2.81M 2.81M 1.24M 4.23M 3.5M 8.5M 2.45M 12.97M -2.54M 277K -40.1M -4.84M 51.7M -14.77M -20.2M -25.14M -19.87M -22.39M
EBIT
2.17M 2.27M 663K 4.23M 3.26M 8.07M 2.27M 12.76M -2.47M 274K -40.11M -4.88M 51.63M 7.95M -20.33M -25.24M -19.93M -22.44M
Depreciation & Amortization
641K 535K 471K 454K 238K 425K 183.28K 202K 1K 3K 10K 40K 67K 113K 115K 85K 45K 45K